254 related articles for article (PubMed ID: 33556413)
1. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Sakurai S; Jojima T; Iijima T; Tomaru T; Usui I; Aso Y
J Diabetes Complications; 2020 Nov; 34(11):107703. PubMed ID: 32883567
[TBL] [Abstract][Full Text] [Related]
3. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
[TBL] [Abstract][Full Text] [Related]
4. Plasma Campesterol Is Positively Associated with Carotid Plaques in Asymptomatic Subjects.
Nunes VS; de Campos EVS; Baracat J; França V; Gomes ÉIL; Coelho RP; Nakandakare ER; Zago VHS; de Faria EC; Quintão ECR
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233298
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia.
Ohta A; Kato H; Ishii S; Nagai Y; Tanaka Y
J Clin Med Res; 2017 Jun; 9(6):476-481. PubMed ID: 28496547
[TBL] [Abstract][Full Text] [Related]
6. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
Rau M; Thiele K; Korbinian Hartmann NU; Möllmann J; Wied S; Böhm M; Scharnagl H; März W; Marx N; Lehrke M
Atherosclerosis; 2021 Aug; 330():8-13. PubMed ID: 34218214
[TBL] [Abstract][Full Text] [Related]
7. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
[TBL] [Abstract][Full Text] [Related]
8. Plasma lathosterol measures rates of cholesterol synthesis and efficiency of dietary phytosterols in reducing the plasma cholesterol concentration.
Nunes VS; Ilha AOG; Ferreira GDS; Bombo RPA; Afonso MS; Lavrador MSF; Machado RM; Nakandakare ER; Quintão ECR; Lottenberg AM
Clinics (Sao Paulo); 2022; 77():100028. PubMed ID: 35397367
[TBL] [Abstract][Full Text] [Related]
9. [Association between very low density lipoprotein cholesterol and cholesterol absorption/synthesis markers in patients with moderate and high risk of coronary heart disease].
Gong Z; Qi Y; Zhao F; Liu J; Wang W; Liu J; Sun J; Xie W; Li Y; Wang M; Qin L; Wang Y; Hao Y; Zhang Q; Chen X; Zhao D
Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Nov; 43(11):936-42. PubMed ID: 26888803
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
[TBL] [Abstract][Full Text] [Related]
11. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
Tricò D; Raggi F; Distaso M; Ferrannini E; Solini A
Diabetes Res Clin Pract; 2022 Aug; 190():109983. PubMed ID: 35803317
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Lupattelli G; Siepi D; De Vuono S; Roscini AR; Crisanti F; Covelli D; Pirro M; Mannarino E
Life Sci; 2012 Jun; 90(21-22):846-50. PubMed ID: 22554491
[TBL] [Abstract][Full Text] [Related]
13. Serum Low Density Lipoprotein Cholesterol Concentration Is Not Dependent on Cholesterol Synthesis and Absorption in Healthy Humans.
Stellaard F; Baumgartner S; Mensink R; Winkens B; Plat J; Lütjohann D
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558527
[TBL] [Abstract][Full Text] [Related]
14. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Niesor EJ; Chaput E; Staempfli A; Blum D; Derks M; Kallend D
Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
[TBL] [Abstract][Full Text] [Related]
15. The coronary artery calcium score is linked to plasma cholesterol synthesis and absorption markers: Brazilian Longitudinal Study of Adult Health.
Nunes VS; Bensenor IM; Lotufo PA; Passarelli M; Nakandakare ER; Quintão ECR
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32579186
[TBL] [Abstract][Full Text] [Related]
16. Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients.
Naruse R; Hori K; Terasawa T; Hara K; Suetsugu M; Takebayashi K; Morita K; Aso Y; Inukai T
Obes Res Clin Pract; 2015; 9(1):67-74. PubMed ID: 25660177
[TBL] [Abstract][Full Text] [Related]
17. Association between Serum Phytosterols and Lipid Levels in a Population-Based Study.
Stanasila L; Lütjohann D; Popp J; Marques-Vidal P
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542686
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens.
Malina DM; Fonseca FA; Barbosa SA; Kasmas SH; Machado VA; França CN; Borges NC; Moreno RA; Izar MC
J Clin Lipidol; 2015; 9(4):542-52. PubMed ID: 26228672
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of lathosterol and phytosterols in relation to age, sex, anthropometric parameters, plasma lipids, and apolipoprotein E phenotype, in 160 Dutch families.
Kempen HJ; de Knijff P; Boomsma DI; van der Voort HA; Gevers Leuven JA; Havekes L
Metabolism; 1991 Jun; 40(6):604-11. PubMed ID: 1865824
[TBL] [Abstract][Full Text] [Related]
20. Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
Lund SS; Sattar N; Salsali A; Neubacher D; Ginsberg HN
Diabetes Obes Metab; 2021 Dec; 23(12):2763-2774. PubMed ID: 34463415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
